XML 53 R54.htm IDEA: XBRL DOCUMENT
v3.19.3

Segments of Business and Geographic Areas - Sales By Segment Of Business (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended
--- | --- | ---
Sep. 29, 2019 | Sep. 30, 2018 | Sep. 29, 2019 | Sep. 30, 2018
Sales by segment of business |  |  |  |
Sales to customers | $ 20,729 | $ 20,348 | $ 61,312 | $ 61,187
Percent Change (as a percent) | 1.90% |  | 0.20% |
U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 10,791 | 10,664 | $ 31,323 | 31,255
Percent Change (as a percent) | 1.20% |  | 0.20% |
International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 9,938 | 9,684 | $ 29,989 | 29,932
Percent Change (as a percent) | 2.60% |  | 0.20% |
CONSUMER |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 3,469 | 3,415 | $ 10,331 | 10,317
Percent Change (as a percent) | 1.60% |  | 0.10% |
CONSUMER | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,394 | 1,370 | $ 4,369 | 4,282
Percent Change (as a percent) | 1.70% |  | 2.00% |
CONSUMER | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 2,075 | 2,045 | $ 5,962 | 6,035
Percent Change (as a percent) | 1.40% |  | (1.20%) |
CONSUMER | Baby Care |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 417 | 472 | $ 1,254 | 1,385
Percent Change (as a percent) | (11.60%) |  | (9.50%) |
CONSUMER | Baby Care | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 91 | 120 | $ 277 | 306
Percent Change (as a percent) | (24.10%) |  | (9.50%) |
CONSUMER | Baby Care | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 326 | 352 | $ 977 | 1,079
Percent Change (as a percent) | (7.30%) |  | (9.50%) |
CONSUMER | Beauty |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,151 | 1,078 | $ 3,443 | 3,271
Percent Change (as a percent) | 6.80% |  | 5.30% |
CONSUMER | Beauty | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 559 | 543 | $ 1,810 | 1,791
Percent Change (as a percent) | 2.90% |  | 1.10% |
CONSUMER | Beauty | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 592 | 535 | $ 1,633 | 1,480
Percent Change (as a percent) | 10.80% |  | 10.40% |
CONSUMER | Oral Care |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 379 | 384 | $ 1,135 | 1,156
Percent Change (as a percent) | (1.40%) |  | (1.80%) |
CONSUMER | Oral Care | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 156 | 158 | $ 462 | 472
Percent Change (as a percent) | (1.10%) |  | (2.10%) |
CONSUMER | Oral Care | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 223 | 226 | $ 673 | 684
Percent Change (as a percent) | (1.60%) |  | (1.70%) |
CONSUMER | OTC |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,098 | 1,048 | $ 3,249 | 3,186
Percent Change (as a percent) | 4.80% |  | 2.00% |
CONSUMER | OTC | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 477 | 440 | $ 1,468 | 1,359
Percent Change (as a percent) | 8.40% |  | 8.00% |
CONSUMER | OTC | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 621 | 608 | $ 1,781 | 1,827
Percent Change (as a percent) | 2.20% |  | (2.50%) |
CONSUMER | Women's Health |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 255 | 269 | $ 733 | 792
Percent Change (as a percent) | (5.30%) |  | (7.40%) |
CONSUMER | Women's Health | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 3 | 3 | $ 9 | 10
Percent Change (as a percent) | (4.00%) |  | (3.80%) |
CONSUMER | Women's Health | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 252 | 266 | $ 724 | 782
Percent Change (as a percent) | (5.40%) |  | (7.50%) |
CONSUMER | Wound Care/Other |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 168 | 164 | $ 516 | 527
Percent Change (as a percent) | 2.40% |  | (2.00%) |
CONSUMER | Wound Care/Other | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 109 | 106 | $ 343 | 344
Percent Change (as a percent) | 1.90% |  | (0.40%) |
CONSUMER | Wound Care/Other | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 59 | 58 | $ 173 | 183
Percent Change (as a percent) | 3.30% |  | (5.00%) |
PHARMACEUTICAL |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 10,877 | 10,346 | $ 31,650 | 30,544
Percent Change (as a percent) | 5.10% |  | 3.60% |
PHARMACEUTICAL | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 6,340 | 6,097 | $ 17,705 | 17,350
Percent Change (as a percent) | 4.00% |  | 2.00% |
PHARMACEUTICAL | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 4,537 | 4,249 | $ 13,945 | 13,194
Percent Change (as a percent) | 6.80% |  | 5.70% |
PHARMACEUTICAL | Immunology |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 3,711 | 3,398 | $ 10,428 | 9,778
Percent Change (as a percent) | 9.30% |  | 6.70% |
PHARMACEUTICAL | Immunology | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 2,582 | 2,400 | $ 7,124 | 6,717
Percent Change (as a percent) | 7.60% |  | 6.10% |
PHARMACEUTICAL | Immunology | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,129 | 998 | $ 3,304 | 3,061
Percent Change (as a percent) | 13.20% |  | 8.00% |
PHARMACEUTICAL | Immunology | REMICADE® |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,136 | 1,379 | $ 3,345 | 4,088
Percent Change (as a percent) | (17.60%) |  | (18.20%) |
PHARMACEUTICAL | Immunology | REMICADE® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 749 | 987 | $ 2,324 | 2,821
Percent Change (as a percent) | (24.10%) |  | (17.60%) |
PHARMACEUTICAL | Immunology | REMICADE® | U.S. Exports |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 88 | 100 | $ 226 | 346
Percent Change (as a percent) | (12.00%) |  | (34.70%) |
PHARMACEUTICAL | Immunology | REMICADE® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 299 | 292 | $ 795 | 921
Percent Change (as a percent) | 2.50% |  | (13.70%) |
PHARMACEUTICAL | Immunology | SIMPONI / SIMPONI ARIA® |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 586 | 536 | $ 1,673 | 1,602
Percent Change (as a percent) | 9.60% |  | 4.50% |
PHARMACEUTICAL | Immunology | SIMPONI / SIMPONI ARIA® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 313 | 281 | $ 857 | 779
Percent Change (as a percent) | 11.60% |  | 10.00% |
PHARMACEUTICAL | Immunology | SIMPONI / SIMPONI ARIA® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 273 | 255 | $ 816 | 823
Percent Change (as a percent) | 7.30% |  | (0.80%) |
PHARMACEUTICAL | Immunology | STELARA® |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,698 | 1,310 | $ 4,661 | 3,712
Percent Change (as a percent) | 29.60% |  | 25.60% |
PHARMACEUTICAL | Immunology | STELARA® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,212 | 889 | $ 3,152 | 2,460
Percent Change (as a percent) | 36.30% |  | 28.10% |
PHARMACEUTICAL | Immunology | STELARA® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 487 | 421 | $ 1,509 | 1,252
Percent Change (as a percent) | 15.70% |  | 20.50% |
PHARMACEUTICAL | Immunology | TREMFYA® |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 290 | 171 | $ 742 | 369
Percent Change (as a percent) | 69.00% |  |  |
PHARMACEUTICAL | Immunology | TREMFYA® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 221 | 143 | $ 565 | 311
Percent Change (as a percent) | 54.30% |  | 81.70% |
PHARMACEUTICAL | Immunology | TREMFYA® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 69 | 28 | $ 177 | 58
PHARMACEUTICAL | Immunology | OTHER IMMUNOLOGY |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 2 | 2 | $ 8 | 7
Percent Change (as a percent) | (4.40%) |  | 13.70% |
PHARMACEUTICAL | Immunology | OTHER IMMUNOLOGY | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 0 | 0 | $ 0 | 0
Percent Change (as a percent) | 0.00% |  | 0.00% |
PHARMACEUTICAL | Immunology | OTHER IMMUNOLOGY | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 2 | 2 | $ 8 | 7
Percent Change (as a percent) | (4.40%) |  | 13.70% |
PHARMACEUTICAL | Infectious Diseases |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 839 | 823 | $ 2,547 | 2,502
Percent Change (as a percent) | 1.90% |  | 1.80% |
PHARMACEUTICAL | Infectious Diseases | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 418 | 345 | $ 1,162 | 1,006
Percent Change (as a percent) | 21.20% |  | 15.50% |
PHARMACEUTICAL | Infectious Diseases | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 421 | 478 | $ 1,385 | 1,496
Percent Change (as a percent) | (12.00%) |  | (7.40%) |
PHARMACEUTICAL | Infectious Diseases | EDURANT® / rilpivirine |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 218 | 202 | $ 639 | 623
Percent Change (as a percent) | 7.90% |  | 2.60% |
PHARMACEUTICAL | Infectious Diseases | EDURANT® / rilpivirine | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 12 | 13 | $ 36 | 42
Percent Change (as a percent) | (7.30%) |  | (14.30%) |
PHARMACEUTICAL | Infectious Diseases | EDURANT® / rilpivirine | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 206 | 189 | $ 603 | 581
Percent Change (as a percent) | 9.00% |  | 3.80% |
PHARMACEUTICAL | Infectious Diseases | PREZISTA® / PREZCOBIX® / REZOLSTA® / SYMTUZA® |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 508 | 490 | $ 1,566 | 1,460
Percent Change (as a percent) | 3.70% |  | 7.30% |
PHARMACEUTICAL | Infectious Diseases | PREZISTA® / PREZCOBIX® / REZOLSTA® / SYMTUZA® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 373 | 297 | $ 1,032 | 847
Percent Change (as a percent) | 25.40% |  | 21.80% |
PHARMACEUTICAL | Infectious Diseases | PREZISTA® / PREZCOBIX® / REZOLSTA® / SYMTUZA® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 135 | 193 | $ 534 | 613
Percent Change (as a percent) | (29.80%) |  | (12.80%) |
PHARMACEUTICAL | Infectious Diseases | OTHER INFECTIOUS DISEASES |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 113 | 131 | $ 342 | 419
Percent Change (as a percent) | (13.90%) |  | (18.60%) |
PHARMACEUTICAL | Infectious Diseases | OTHER INFECTIOUS DISEASES | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 33 | 35 | $ 94 | 117
Percent Change (as a percent) | (4.30%) |  | (19.60%) |
PHARMACEUTICAL | Infectious Diseases | OTHER INFECTIOUS DISEASES | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 80 | 96 | $ 248 | 302
Percent Change (as a percent) | (17.40%) |  | (18.20%) |
PHARMACEUTICAL | Neuroscience |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,595 | 1,490 | $ 4,762 | 4,577
Percent Change (as a percent) | 7.10% |  | 4.00% |
PHARMACEUTICAL | Neuroscience | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 785 | 651 | $ 2,172 | 1,914
Percent Change (as a percent) | 20.70% |  | 13.50% |
PHARMACEUTICAL | Neuroscience | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 810 | 839 | $ 2,590 | 2,663
Percent Change (as a percent) | (3.50%) |  | (2.70%) |
PHARMACEUTICAL | Neuroscience | CONCERTA® / methylphenidate |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 193 | 157 | $ 544 | 513
Percent Change (as a percent) | 23.50% |  | 6.10% |
PHARMACEUTICAL | Neuroscience | CONCERTA® / methylphenidate | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 84 | 57 | $ 196 | 191
Percent Change (as a percent) | 48.20% |  | 2.90% |
PHARMACEUTICAL | Neuroscience | CONCERTA® / methylphenidate | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 109 | 100 | $ 348 | 322
Percent Change (as a percent) | 9.40% |  | 8.00% |
PHARMACEUTICAL | Neuroscience | INVEGA SUSTENNA® / XEPLION® / INVEGA TRINZA® / TREVICTA® |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 851 | 749 | $ 2,459 | 2,165
Percent Change (as a percent) | 13.70% |  | 13.60% |
PHARMACEUTICAL | Neuroscience | INVEGA SUSTENNA® / XEPLION® / INVEGA TRINZA® / TREVICTA® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 554 | 468 | $ 1,543 | 1,306
Percent Change (as a percent) | 18.30% |  | 18.10% |
PHARMACEUTICAL | Neuroscience | INVEGA SUSTENNA® / XEPLION® / INVEGA TRINZA® / TREVICTA® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 297 | 281 | $ 916 | 859
Percent Change (as a percent) | 5.90% |  | 6.70% |
PHARMACEUTICAL | Neuroscience | RISPERDAL CONSTA® |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 167 | 175 | $ 528 | 559
Percent Change (as a percent) | (3.80%) |  | (5.40%) |
PHARMACEUTICAL | Neuroscience | RISPERDAL CONSTA® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 79 | 76 | $ 237 | 238
Percent Change (as a percent) | 4.90% |  | (0.50%) |
PHARMACEUTICAL | Neuroscience | RISPERDAL CONSTA® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 89 | 99 | $ 292 | 321
Percent Change (as a percent) | (10.50%) |  | (9.10%) |
PHARMACEUTICAL | Neuroscience | OTHER NEUROSCIENCE |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 384 | 409 | $ 1,231 | 1,340
Percent Change (as a percent) | (6.60%) |  | (8.20%) |
PHARMACEUTICAL | Neuroscience | OTHER NEUROSCIENCE | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 68 | 50 | $ 196 | 179
Percent Change (as a percent) | 35.30% |  | 9.70% |
PHARMACEUTICAL | Neuroscience | OTHER NEUROSCIENCE | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 316 | 359 | $ 1,035 | 1,161
Percent Change (as a percent) | (12.50%) |  | (10.90%) |
PHARMACEUTICAL | Oncology |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 2,761 | 2,588 | $ 7,976 | 7,355
Percent Change (as a percent) | 6.70% |  | 8.40% |
PHARMACEUTICAL | Oncology | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,171 | 1,250 | $ 3,146 | 3,268
Percent Change (as a percent) | (6.30%) |  | (3.70%) |
PHARMACEUTICAL | Oncology | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,590 | 1,338 | $ 4,830 | 4,087
Percent Change (as a percent) | 18.80% |  | 18.20% |
PHARMACEUTICAL | Oncology | DARZALEX® |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 765 | 498 | $ 2,168 | 1,441
Percent Change (as a percent) | 53.50% |  | 50.40% |
PHARMACEUTICAL | Oncology | DARZALEX® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 402 | 318 | $ 1,123 | 880
Percent Change (as a percent) | 26.10% |  | 27.60% |
PHARMACEUTICAL | Oncology | DARZALEX® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 363 | 180 | $ 1,045 | 561
Percent Change (as a percent) |  |  | 86.20% |
PHARMACEUTICAL | Oncology | IMBRUVICA® |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 921 | 705 | $ 2,536 | 1,912
Percent Change (as a percent) | 30.60% |  | 32.60% |
PHARMACEUTICAL | Oncology | IMBRUVICA® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 447 | 334 | $ 1,163 | 811
Percent Change (as a percent) | 34.00% |  | 43.50% |
PHARMACEUTICAL | Oncology | IMBRUVICA® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 475 | 371 | $ 1,373 | 1,101
Percent Change (as a percent) | 27.60% |  | 24.60% |
PHARMACEUTICAL | Oncology | VELCADE® |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 149 | 271 | $ 636 | 864
Percent Change (as a percent) | (44.80%) |  | (26.30%) |
PHARMACEUTICAL | Oncology | VELCADE® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 0 | 0 | $ 0 | 0
Percent Change (as a percent) | 0.00% |  | 0.00% |
PHARMACEUTICAL | Oncology | VELCADE® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 149 | 271 | $ 636 | 864
Percent Change (as a percent) | (44.80%) |  | (26.30%) |
PHARMACEUTICAL | Oncology | ZYTIGA® / abiraterone acetate |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 741 | 958 | $ 2,118 | 2,712
Percent Change (as a percent) | (22.70%) |  | (21.90%) |
PHARMACEUTICAL | Oncology | ZYTIGA® / abiraterone acetate | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 233 | 527 | $ 616 | 1,420
Percent Change (as a percent) | (55.80%) |  | (56.60%) |
PHARMACEUTICAL | Oncology | ZYTIGA® / abiraterone acetate | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 508 | 431 | $ 1,502 | 1,292
Percent Change (as a percent) | 17.80% |  | 16.20% |
PHARMACEUTICAL | Oncology | OTHER ONCOLOGY |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 186 | 156 | $ 519 | 426
Percent Change (as a percent) | 18.80% |  | 21.60% |
PHARMACEUTICAL | Oncology | OTHER ONCOLOGY | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 91 | 71 | $ 245 | 157
Percent Change (as a percent) | 26.70% |  | 54.70% |
PHARMACEUTICAL | Oncology | OTHER ONCOLOGY | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 95 | 85 | $ 274 | 269
Percent Change (as a percent) | 12.20% |  | 2.10% |
PHARMACEUTICAL | Pulmonary Hypertension |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 654 | 656 | $ 2,000 | 1,906
Percent Change (as a percent) | (0.30%) |  | 4.90% |
PHARMACEUTICAL | Pulmonary Hypertension | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 427 | 425 | $ 1,296 | 1,215
Percent Change (as a percent) | 0.50% |  | 6.60% |
PHARMACEUTICAL | Pulmonary Hypertension | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 227 | 231 | $ 704 | 691
Percent Change (as a percent) | (1.60%) |  | 1.90% |
PHARMACEUTICAL | Pulmonary Hypertension | OPSUMIT® |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 347 | 310 | $ 1,001 | 892
Percent Change (as a percent) | 11.70% |  | 12.20% |
PHARMACEUTICAL | Pulmonary Hypertension | OPSUMIT® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 206 | 182 | $ 581 | 511
Percent Change (as a percent) | 12.90% |  | 13.70% |
PHARMACEUTICAL | Pulmonary Hypertension | OPSUMIT® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 140 | 128 | $ 419 | 381
Percent Change (as a percent) | 10.10% |  | 10.20% |
PHARMACEUTICAL | Pulmonary Hypertension | TRACLEER® / bosentan |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 65 | 139 | $ 285 | 422
Percent Change (as a percent) | (52.70%) |  | (32.40%) |
PHARMACEUTICAL | Pulmonary Hypertension | TRACLEER® / bosentan | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 19 | 69 | $ 121 | 208
Percent Change (as a percent) | (72.40%) |  | (41.80%) |
PHARMACEUTICAL | Pulmonary Hypertension | TRACLEER® / bosentan | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 46 | 70 | $ 164 | 214
Percent Change (as a percent) | (32.80%) |  | (23.30%) |
PHARMACEUTICAL | Pulmonary Hypertension | UPTRAVI® |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 210 | 171 | $ 611 | 482
Percent Change (as a percent) | 23.40% |  | 26.80% |
PHARMACEUTICAL | Pulmonary Hypertension | UPTRAVI® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 185 | 154 | $ 536 | 433
Percent Change (as a percent) | 20.20% |  | 23.90% |
PHARMACEUTICAL | Pulmonary Hypertension | UPTRAVI® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 25 | 17 | $ 75 | 49
Percent Change (as a percent) | 52.10% |  | 52.80% |
PHARMACEUTICAL | Pulmonary Hypertension | OTHER |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 31 | 36 | $ 103 | 110
Percent Change (as a percent) | (12.60%) |  | (6.40%) |
PHARMACEUTICAL | Pulmonary Hypertension | OTHER | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 17 | 20 | $ 58 | 63
Percent Change (as a percent) | (10.10%) |  | (8.90%) |
PHARMACEUTICAL | Pulmonary Hypertension | OTHER | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 15 | 16 | $ 46 | 47
Percent Change (as a percent) | (15.40%) |  | (3.00%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,316 | 1,391 | $ 3,936 | 4,426
Percent Change (as a percent) | (5.40%) |  | (11.10%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 955 | 1,026 | $ 2,804 | 3,230
Percent Change (as a percent) | (6.90%) |  | (13.20%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 360 | 365 | $ 1,131 | 1,196
Percent Change (as a percent) | (1.30%) |  | (5.40%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | XARELTO® |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 613 | 612 | $ 1,704 | 1,869
Percent Change (as a percent) | 0.10% |  | (8.90%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | XARELTO® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 613 | 612 | $ 1,704 | 1,869
Percent Change (as a percent) | 0.10% |  | (8.90%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | XARELTO® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 0 | 0 | $ 0 | 0
Percent Change (as a percent) | 0.00% |  | 0.00% |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | INVOKANA® / INVOKAMET® |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 179 | 190 | $ 558 | 653
Percent Change (as a percent) | (5.80%) |  | (14.60%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | INVOKANA® / INVOKAMET® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 125 | 150 | $ 411 | 523
Percent Change (as a percent) | (16.60%) |  | (21.30%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | INVOKANA® / INVOKAMET® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 55 | 40 | $ 147 | 130
Percent Change (as a percent) | 33.90% |  | 12.30% |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | PROCRIT® / EPREX® |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 198 | 255 | $ 607 | 767
Percent Change (as a percent) | (22.40%) |  | (20.90%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | PROCRIT® / EPREX® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 126 | 178 | $ 387 | 523
Percent Change (as a percent) | (29.60%) |  | (26.10%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | PROCRIT® / EPREX® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 72 | 77 | $ 220 | 244
Percent Change (as a percent) | (5.70%) |  | (9.80%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | OTHER |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 325 | 334 | $ 1,067 | 1,137
Percent Change (as a percent) | (2.20%) |  | (6.10%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | OTHER | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 91 | 86 | $ 302 | 315
Percent Change (as a percent) | 8.10% |  | (3.80%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | OTHER | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 234 | 248 | $ 765 | 822
Percent Change (as a percent) | (5.70%) |  | (6.90%) |
MEDICAL DEVICES |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 6,383 | 6,587 | $ 19,331 | 20,326
Percent Change (as a percent) | (3.10%) |  | (4.90%) |
MEDICAL DEVICES | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 3,057 | 3,197 | $ 9,249 | 9,623
Percent Change (as a percent) | (4.40%) |  | (3.90%) |
MEDICAL DEVICES | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 3,326 | 3,390 | $ 10,082 | 10,703
Percent Change (as a percent) | (1.90%) |  | (5.80%) |
MEDICAL DEVICES | Diabetes Care |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 0 | 315 | $ 0 | 1,009
MEDICAL DEVICES | Diabetes Care | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | 0 | 125 | 0 | 371
MEDICAL DEVICES | Diabetes Care | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | 0 | 190 | 0 | 638
MEDICAL DEVICES | Interventional Solutions |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 741 | 653 | $ 2,223 | 1,960
Percent Change (as a percent) | 13.40% |  | 13.40% |
MEDICAL DEVICES | Interventional Solutions | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 357 | 320 | $ 1,066 | 947
Percent Change (as a percent) | 11.50% |  | 12.60% |
MEDICAL DEVICES | Interventional Solutions | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 382 | 333 | $ 1,156 | 1,013
Percent Change (as a percent) | 15.30% |  | 14.20% |
MEDICAL DEVICES | Orthopaedics |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 2,138 | 2,111 | $ 6,566 | 6,623
Percent Change (as a percent) | 1.20% |  | (0.90%) |
MEDICAL DEVICES | Orthopaedics | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,301 | 1,284 | $ 3,950 | 3,923
Percent Change (as a percent) | 1.20% |  | 0.70% |
MEDICAL DEVICES | Orthopaedics | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 837 | 827 | $ 2,616 | 2,700
Percent Change (as a percent) | 1.20% |  | (3.10%) |
MEDICAL DEVICES | Orthopaedics | HIPS |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 336 | 330 | $ 1,061 | 1,053
Percent Change (as a percent) | 1.70% |  | 0.70% |
MEDICAL DEVICES | Orthopaedics | HIPS | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 204 | 201 | $ 633 | 621
Percent Change (as a percent) | 1.10% |  | 1.80% |
MEDICAL DEVICES | Orthopaedics | HIPS | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 133 | 129 | $ 428 | 432
Percent Change (as a percent) | 2.70% |  | (0.80%) |
MEDICAL DEVICES | Orthopaedics | KNEES |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 344 | 341 | $ 1,085 | 1,110
Percent Change (as a percent) | 1.20% |  | (2.20%) |
MEDICAL DEVICES | Orthopaedics | KNEES | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 209 | 215 | $ 650 | 672
Percent Change (as a percent) | (2.70%) |  | (3.30%) |
MEDICAL DEVICES | Orthopaedics | KNEES | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 136 | 126 | $ 435 | 438
Percent Change (as a percent) | 7.90% |  | (0.60%) |
MEDICAL DEVICES | Orthopaedics | TRAUMA |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 677 | 654 | $ 2,034 | 2,025
Percent Change (as a percent) | 3.50% |  | 0.40% |
MEDICAL DEVICES | Orthopaedics | TRAUMA | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 415 | 395 | $ 1,239 | 1,196
Percent Change (as a percent) | 5.10% |  | 3.60% |
MEDICAL DEVICES | Orthopaedics | TRAUMA | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 262 | 259 | $ 795 | 829
Percent Change (as a percent) | 1.00% |  | (4.10%) |
MEDICAL DEVICES | Orthopaedics | SPINE & OTHER |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 778 | 786 | $ 2,384 | 2,435
Percent Change (as a percent) | (0.90%) |  | (2.10%) |
MEDICAL DEVICES | Orthopaedics | SPINE & OTHER | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 472 | 473 | $ 1,427 | 1,434
Percent Change (as a percent) | (0.20%) |  | (0.50%) |
MEDICAL DEVICES | Orthopaedics | SPINE & OTHER | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 306 | 313 | $ 957 | 1,001
Percent Change (as a percent) | (2.00%) |  | (4.40%) |
MEDICAL DEVICES | Surgery |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 2,311 | 2,376 | $ 7,059 | 7,314
Percent Change (as a percent) | (2.70%) |  | (3.50%) |
MEDICAL DEVICES | Surgery | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 940 | 1,016 | $ 2,867 | 3,031
Percent Change (as a percent) | (7.40%) |  | (5.40%) |
MEDICAL DEVICES | Surgery | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,371 | 1,360 | $ 4,192 | 4,283
Percent Change (as a percent) | 0.80% |  | (2.10%) |
MEDICAL DEVICES | Surgery | ADVANCED |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,010 | 976 | $ 3,019 | 2,947
Percent Change (as a percent) | 3.60% |  | 2.40% |
MEDICAL DEVICES | Surgery | ADVANCED | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 409 | 421 | $ 1,209 | 1,216
Percent Change (as a percent) | (2.80%) |  | (0.60%) |
MEDICAL DEVICES | Surgery | ADVANCED | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 602 | 555 | $ 1,811 | 1,731
Percent Change (as a percent) | 8.30% |  | 4.60% |
MEDICAL DEVICES | Surgery | GENERAL |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,101 | 1,080 | $ 3,309 | 3,376
Percent Change (as a percent) | 1.90% |  | (2.00%) |
MEDICAL DEVICES | Surgery | GENERAL | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 443 | 423 | $ 1,311 | 1,282
Percent Change (as a percent) | 4.70% |  | 2.30% |
MEDICAL DEVICES | Surgery | GENERAL | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 659 | 657 | $ 1,998 | 2,094
Percent Change (as a percent) | 0.20% |  | (4.60%) |
MEDICAL DEVICES | Surgery | SPECIALTY |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 200 | 320 | $ 731 | 991
Percent Change (as a percent) | (37.40%) |  | (26.20%) |
MEDICAL DEVICES | Surgery | SPECIALTY | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 88 | 172 | $ 347 | 533
Percent Change (as a percent) | (48.00%) |  | (34.90%) |
MEDICAL DEVICES | Surgery | SPECIALTY | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 110 | 148 | $ 383 | 458
Percent Change (as a percent) | (25.00%) |  | (16.20%) |
MEDICAL DEVICES | Vision |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,193 | 1,132 | $ 3,483 | 3,420
Percent Change (as a percent) | 5.40% |  | 1.80% |
MEDICAL DEVICES | Vision | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 459 | 452 | $ 1,366 | 1,351
Percent Change (as a percent) | 1.40% |  | 1.10% |
MEDICAL DEVICES | Vision | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 734 | 680 | $ 2,117 | 2,069
Percent Change (as a percent) | 8.00% |  | 2.30% |
MEDICAL DEVICES | Vision | CONTACT LENSES / OTHER |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 893 | 835 | $ 2,559 | 2,486
Percent Change (as a percent) | 7.00% |  | 2.90% |
MEDICAL DEVICES | Vision | CONTACT LENSES / OTHER | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 339 | 319 | $ 993 | 948
Percent Change (as a percent) | 6.20% |  | 4.70% |
MEDICAL DEVICES | Vision | CONTACT LENSES / OTHER | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 555 | 516 | $ 1,566 | 1,538
Percent Change (as a percent) | 7.40% |  | 1.80% |
MEDICAL DEVICES | Vision | SURGICAL |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 299 | 297 | $ 923 | 934
Percent Change (as a percent) | 0.90% |  | (1.10%) |
MEDICAL DEVICES | Vision | SURGICAL | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 120 | 133 | $ 373 | 403
Percent Change (as a percent) | (10.00%) |  | (7.40%) |
MEDICAL DEVICES | Vision | SURGICAL | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 180 | $ 164 | $ 551 | $ 531
Percent Change (as a percent) | 9.90% |  | 3.70% |

X
- Definition Percentage change in sales by segment of business. + References No definition available. + Details
Name: | jnj_PercentageChangeInSalesBySegmentOfBusiness
Namespace Prefix: | jnj_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingInformationRevenueAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_BabyCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_BeautyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OralCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OTCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_WomensHealthMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_WoundCareandOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_ImmunologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_RemicadeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=jnj_UNITEDSTATESExportsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_SimponiSimponiAriaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_StelaraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_TremfyaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherImmunologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_InfectiousDiseasesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_EDURANTrilpivirineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherInfectiousDiseasesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_NeuroscienceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_CONCERTAMethylphenidateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_RISPERDALCONSTAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OTHERNEUROSCIENCEMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_OncologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_DARZALEXMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_IMBRUVICAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_VELCADEMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_ZYTIGAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherOncologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_PulmonaryHypertensionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OPSUMITMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_TRACLEERMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_UPTRAVIMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_CardiovascularMetabolismOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_XareltoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_INVOKANAINVOKAMETMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_PROCRITEPREXMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_DiabetesCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_InterventionalSolutionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_OrthopaedicsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_HIPSMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_KNEESMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_TRAUMAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_SPINEOTHERMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_SurgeryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_ADVANCEDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_GENERALMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_SPECIALTYMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_VisionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_CONTACTLENSESOTHERMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_SURGICALMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |